Float Short %

22.08

Margin Of Safety %

Put/Call OI Ratio

0.41

EPS Next Q Diff

-0.36

EPS Last/This Y

EPS This/Next Y

-1.35

Price

8.19

Target Price

56.78

Analyst Recom

Performance Q

-51.19

Relative Volume

0.67

Beta

2.59

Ticker: CRBP

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-01-23	CRBP	10.81	0.11	0.46	6769
2025-01-24	CRBP	10.53	0.23	1.88	8839
2025-01-27	CRBP	9.74	0.24	0.74	9007
2025-01-28	CRBP	9.91	0.27	9.83	9442
2025-01-29	CRBP	9.63	0.27	12.22	9485
2025-01-30	CRBP	9.91	0.36	1.06	10241
2025-01-31	CRBP	9.79	0.36	0.77	10340
2025-02-03	CRBP	9.53	0.37	7.41	10394
2025-02-04	CRBP	9.66	0.37	1.93	10441
2025-02-05	CRBP	11.35	0.39	2.06	10547
2025-02-06	CRBP	11.31	0.42	0.43	10759
2025-02-07	CRBP	10.18	0.42	2.27	11240
2025-02-10	CRBP	9.8	0.42	0.77	11284
2025-02-11	CRBP	8.75	0.43	0.52	11377
2025-02-12	CRBP	9.02	0.43	0.36	11489
2025-02-13	CRBP	9.48	0.45	10.15	11903
2025-02-14	CRBP	8.5	0.51	1.02	12421
2025-02-18	CRBP	8.21	0.46	0.95	12859
2025-02-19	CRBP	7.82	0.45	7.52	13149
2025-02-20	CRBP	8.29	0.42	3.69	12923
2025-02-21	CRBP	8.2	0.41	0.87	12838
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-01-23	CRBP	10.79	30.5	-	-4.38
2025-01-24	CRBP	10.52	30.5	-	-4.38
2025-01-27	CRBP	9.75	30.5	-	-4.38
2025-01-28	CRBP	9.91	30.5	-	-4.38
2025-01-29	CRBP	9.63	30.5	-	-4.38
2025-01-30	CRBP	9.90	30.5	-	-4.38
2025-01-31	CRBP	9.82	30.5	-	-4.38
2025-02-03	CRBP	9.51	30.5	-	-4.38
2025-02-04	CRBP	9.66	30.5	-	-4.38
2025-02-05	CRBP	11.35	30.5	-	-4.38
2025-02-06	CRBP	11.32	30.5	-	-4.38
2025-02-07	CRBP	10.11	30.5	-	-4.38
2025-02-10	CRBP	9.78	30.5	-	-4.38
2025-02-11	CRBP	8.76	30.5	-	-4.38
2025-02-12	CRBP	9.05	30.5	-	-4.38
2025-02-13	CRBP	9.48	30.5	-	-4.38
2025-02-14	CRBP	8.51	30.5	-	-4.38
2025-02-18	CRBP	8.20	30.5	-	-4.38
2025-02-19	CRBP	7.80	30.5	-	-4.38
2025-02-20	CRBP	8.29	30.5	-	-4.38
2025-02-21	CRBP	8.19	30.5	-	-4.38
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-01-23	CRBP	37.44	10.38	22.14
2025-01-24	CRBP	37.43	10.38	22.14
2025-01-27	CRBP	37.44	8.71	22.14
2025-01-28	CRBP	37.44	8.71	22.01
2025-01-29	CRBP	37.43	8.71	22.01
2025-01-30	CRBP	37.44	8.71	22.01
2025-01-31	CRBP	37.43	8.71	22.01
2025-02-03	CRBP	37.43	6.50	22.01
2025-02-04	CRBP	37.43	6.50	22.01
2025-02-05	CRBP	37.43	6.50	22.01
2025-02-06	CRBP	37.44	6.50	22.01
2025-02-07	CRBP	37.44	6.50	22.01
2025-02-10	CRBP	37.44	5.96	22.26
2025-02-11	CRBP	33.08	5.96	22.26
2025-02-12	CRBP	33.08	5.96	21.55
2025-02-13	CRBP	33.08	5.96	21.55
2025-02-14	CRBP	33.04	5.96	21.55
2025-02-18	CRBP	33.04	-1.80	21.55
2025-02-19	CRBP	25.57	-1.80	22.08
2025-02-20	CRBP	25.58	-1.80	22.08
2025-02-21	CRBP	25.57	-1.80	22.08
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-1.15

Avg. EPS Est. Current Quarter

-1.26

Avg. EPS Est. Next Quarter

-1.51

Insider Transactions

25.57

Institutional Transactions

-1.8

Beta

2.59

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

97.2

Max Drawdown 5-Year %

-99.2

Target Price

56.78

P/E

Forward P/E

PEG

P/S

P/B

0.66

P/Free Cash Flow

EPS

-4.7

Average EPS Est. Cur. Y

-4.38

EPS Next Y. (Est.)

-5.73

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.67

Return on Equity vs Sector %

-45

Return on Equity vs Industry %

-29.3

EPS 1 7Days Diff

-0.2

EPS 1 30Days Diff

-0.16

EBIT Estimation

Corbus Pharmaceuticals Holdings

Sector: Healthcare

Industry: Biotechnology

Employees: 19

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

stock quote shares CRBP – Corbus Pharmaceuticals Holdings, Inc. Stock Price stock today

news today CRBP – Corbus Pharmaceuticals Holdings, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch CRBP – Corbus Pharmaceuticals Holdings, Inc. yahoo finance google finance

stock history CRBP – Corbus Pharmaceuticals Holdings, Inc. invest stock market

stock prices CRBP premarket after hours

ticker CRBP fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: CRBP

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y